Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02669758 · ClinicalTrials.gov registry record · Phase 3

A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

A Phase 3 study of Schizophrenia, sponsored by Alkermes.

Completed
Registry status
Phase 3
Development phase
281
Enrollment target
20
Study locations

NCT02669758: Completed Phase 3 study of Schizophrenia, sponsored by Alkermes.

NCT02669758 is a Phase 3 study of Schizophrenia that has completed, run by Alkermes. The registered enrollment target is 281 participants, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02669758, a Phase 3 study of Schizophrenia, has completed, sponsored by Alkermes.

COMPLETED
Registry status
Phase 3
Development phase
281 participants
Enrollment target
20
Study locations

Study Summary

The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.

Conditions Studied

Interventions

  • DRUG ALKS 3831

Study Locations (20)

Other

  • Alkermes Investigational Site - Burgas
  • Alkermes Investigational Site - Kazanlak
  • Alkermes Investigational Site - Lovech
  • Alkermes Investigational Site - Novi Iskar
  • Alkermes Investigational Site - Plovdiv
  • Alkermes Investigational Site - Sofia

California

  • Alkermes Investigational Site - Culver City
  • Alkermes Investigational Site - Garden Grove
  • Alkermes Investigational Site - Lemon Grove
  • Alkermes Investigational Site - Orange
  • Alkermes Investigational Site - San Diego

Arkansas

  • Alkermes Investigational Site - Little Rock
  • Alkermes Investigational Site - Springdale

Florida

  • Alkermes Investigational Site - Miami

Illinois

  • Alkermes Investigational Site - Chicago

Missouri

  • Alkermes Investigational Site - St Louis

Nevada

  • Alkermes Investigational Site - Las Vegas

New Jersey

  • Alkermes Investigational Site - Marlton

Trial Details

FieldValue
Enrollment Target 281 participants
Start Date 2016-01-20
Est. Completion 2018-06-29
Phase Phase 3
Alkermes

66 total trials

What the finished NCT02669758 record still lists

NCT02669758 is an interventional study that assigns participants to a tested intervention. The registered 281 participants enrollment target is mid-sized for trials with a published cap, above the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (29% higher).

The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 1 intervention - of which ALKS 3831 is the first listed.

NCT02669758 names 20 study sites across 10 states, led by Other, California, Arkansas.

Frequently Asked Questions

What is clinical trial NCT02669758 about?

NCT02669758 is a clinical study titled "A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia". The primary objective of this study is to evaluate the long term safety and tolerability of ALKS 3831 in subjects with schizophrenia.

What is the current status of trial NCT02669758?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 281 participants. The study started on 2016-01-20. Estimated completion is 2018-06-29.

What conditions does trial NCT02669758 study?

This clinical trial studies the following conditions: Schizophrenia.

What interventions are being tested in trial NCT02669758?

The interventions under investigation include: ALKS 3831 (DRUG).

Who is sponsoring clinical trial NCT02669758?

This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02669758 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Schizophrenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02669758's enrollment target sits among peer trials

281 69th of 315 higher than 246 of 315 other Schizophrenia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04521231 · 281 participants · Phase 1

    A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

  • NCT06190730 · 281 participants · NA

    REmote Symptom COllection to improVE postopeRative Care

  • NCT02860364 · 282 participants · NA

    Comparing Hypothermic Temperatures During Hemiarch Surgery

  • NCT04867395 · 282 participants · NA

    A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02669758, the US trial registry maintained by the National Library of Medicine. NCT02669758 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.